Comparative analysis of vaccine and disease induced immunity and immunological evaluation of COVID-19 vaccines on effectiveness and safety
Acronym
COVIDIMMUNITY
Description of the granted funding
A novel coronavirus, SARS-CoV-2 started the first coronavirus pandemic in early 2020. The virus spreads mainly via respiratory droplets and occasionally the disease leads to a severe lower respiratory tract infection, acute respiratory failure and death. Globally, as of June 2020 there have been nearly 6,5 million cases and 400 000 deaths due to COVID-19 infection. Our research consortium concentrates on analyzing the activation and specificity of antibody and cell-mediated immunity in COVID-19 infected and vaccinated individuals. We intend to identify the viral targets of protective immunity and in longitudinal follow-up studies analyze the natural infection and COVID-19 vaccine-induced immunity at individual and population level. The study has a significant public health impact and the data produced by the project is likely to enhance pandemic preparedness and response as well as to direct coronavirus vaccination policy in Finland.
Show moreStarting year
2020
End year
2022
Granted funding
Role in consortium of the Academy of Finland
Leader
Funder
Research Council of Finland
Funding instrument
Targeted Academy projects
Other information
Funding decision number
336410
Fields of science
Biomedicine
Research fields
Biolääketieteet
Themes
Lisätalousarvio III 2020
Identified topics
covid, pandemic, vaccines